Neurol Neurochir Pol. 2004;38(1 Suppl 1):S53-6
Bartosik-Psujek H, Stelmasiak Z.
Katedra i Klinika Neurologii, Akademia Medyczna, ul. Jaczewskiego 8,
20-954 Lublin.
Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs).
The importance of NABs has not been completely explained, however it is generally reckoned that they might be one of the factors diminishing treatment efficacy.
This paper presents the consequences of NABs formation during IFN therapy.
Differences
of immunogenicity between the interferon beta products with regard to their
structure, formulation, dose, route of administration were presented and
the influence of NABs on the biological and clinical activity of IFN beta
therapy was shown.